Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control armDKK1 levels highly correlated with clinical activity in CRC populationORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populationsPreparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker p ...